G_CS_52 GLP Injectable Therapies Guidance

The purpose of this guidance is to implement a co-ordinated and uniform approach to strategic operational management or clinical management.

People with type 2 diabetes may require treatment with GLP-1 therapies to manage their condition when insulin may not be the most appropriate choice in treatment due to potential further weight gain.

 Recently the embargo of prescribing a GLP1 with insulin has been lifted for three of the four GLP1 drugs (Exenatide, Liraglutide & Lixisenatide ) . Thus enabling patient receiving a basal insulin only to commence this therapy or if already taking a GLP1 can be introduced.

 The need to promote patient independence and choice as well as using safe, effective and appropriate use of resources is recognised by LCHS.

 There is now an expectation that community nurses with the appropriate diabetes management skills and competencies will be involved in the management of type 2 diabetes using GLP-1 injectable therapies within the community setting.

 Whilst the guidelines within this policy will provide the information for safe, sound practice, the nurse must holistically assess the individual patient’s needs based upon their circumstances.

Document Type: